Hutchison China MediTech Ltd ("Chi-Med"): Focused on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. Chi-Med has a portfolio of 8 drugs in clinical development from own discovery engine in its Innovation platform and a cash generating Commercial platform with 2,500+ sales reps. Launched fruquintinib, partnered with Eil Lilly, in late stage colorectal cancer in China in November 2018. Global collaboration with AstraZeneca in two registration enabling studies with savolitinib in Tagrisso refractory lung cancer that is MET+ and EGFRm+ (global) and MET Exon 14 deletion NSCLC (China). Potential to start two registration programs globally in 2020.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Asia, US - Middle Atlantic
Clinical Stage
Marketed, Phase III, Phase l or ll
Disease Space
Anti-inflammatory, Autoimmune, Immunotherapy, Oncology
Finance
Profitable, Revenues
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Website:
http://www.chi-med.com/
Address:
230 Park Ave
10th Fl
New York, NY 10169
United States
Presentation:
Company Presentation

Company Participants at Solebury Trout Management Access SF 2020

  • Christian Hogg, CEO
  • Mark Lee, SVP Corporate Finance and Development
  • May Wang, SVP BD & Strategic Alliances
  • Weiguo Su, PhD, EVP & CSO
More info:
Send Message to Request Information
My account:
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Hutchison China Meditech Ltd Sponsored ADR

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Capital International, Inc. 3.72 4,961,260 163.23 13F 6/30/20
Capital Research & Management Co. (International Investors) 3.13 4,167,563 137.11 13F 6/30/20
M&G Investment Management Ltd. 2.60 3,462,875 113.93 13F 6/30/20
Wellington Management Co. LLP 2.06 2,748,909 90.44 13F 6/30/20
Sands Capital Management LLC 1.88 2,501,976 82.32 13F 6/30/20
Capital Research & Management Co. (World Investors) 1.70 2,271,707 74.74 Funds 6/30/20
Schroder Investment Management (Singapore) Ltd. 1.57 2,091,335 68.80 13F 6/30/20
BlackRock Fund Advisors 1.29 1,722,090 56.66 13F 6/30/20
Schroder Investment Management (Hong Kong) Ltd. 1.28 1,713,179 56.36 13F 6/30/20
Zeal Asset Management Ltd. 1.12 1,487,970 48.95 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.